Jardiance Duo 12.5mg/850mg Film-Coated Tablets

Manufacturer
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG
 
Contents
Per 12.5 mg/850 mg FC tab Empagliflozin 12.5 mg, metformin HCl 850 mg. 
 
Indication
Adjunct to diet & exercise to improve glycaemic control in adult patients w/ type 2 DM when treatment w/ both empagliflozin & metformin is appropriate; inadequately controlled w/ metformin or empagliflozin alone or in combination w/ other glucose-lowering products including insulin & already treated w/ empagliflozin & metformin co-administered as separate tab. Reduction of CV death risks in patients w/ type 2 DM & established CV disease.
 
Instruction
Should be taken with food: Take w/ meals to reduce GI discomfort.
 
Drug interaction
Empagliflozin: Increased risk of dehydration & hypotension w/ thiazide & loop diuretics. Increased risk of hypoglycaemia w/ insulin & insulin secretagogues eg, sulfonylureas. Increased overall exposure w/ gemfibrozil, rifampicin, probenecid. Metformin: Increased risk of lactic acidosis w/ alcohol, loop diuretics. Monitor blood glucose w/ glucocorticoids, local & systemic tetracosactides, β₂-agonists, danazol, high-dose chlorpromazine. Decreased blood glucose levels w/ ACE inhibitors. Affected glucose control w/ Ca-channel blockers. Potentiated antihyperglycaemic action w/ β-blockers. Reduced clearance w/ cimetidine. Increased elimination rate of vit K antagonists. Enhanced absorption by nifedipine. Reduced efficacy w/ verapamil. Increased GI absorption & efficacy w/ rifampicin. Increased plasma conc w/ dolutegravir, crizotinib, olaparib, daclatasvir, vandetanib.